深度学习驱动的SN3-1的发现,一种强大的NLRP3抑制剂,具有治疗炎症疾病的治疗潜力
Cheng Shi1, Tongfei Gao1, Weiping Lyu1
1State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Journal of medicinal chemistry
|September 20, 2024
概括
研究人员开发了SN3-1,这是一种强大的口服抑制剂,向NLRP3炎症酶,在许多疾病中至关重要. 这种使用人工智能发现的新型化合物显示出治疗NLRP3相关疾病的前景.
科学领域:
- 药物发现 药物发现 药物发现
- 免疫学 免疫学 免疫学
- 计算化学计算化学
背景情况:
- NLRP3炎症酶与许多难以治疗的人类疾病有关.
- 准NLRP3炎症酶体是一个重要的治疗机会.
研究的目的:
- 报告SN3-1的发展,一种新的,口服强大的NLRP3抑制剂.
- 展示一种利用基于深度学习的分子生成模型的药物发现策略.
主要方法:
- 采用深度学习生成模型进行快速碎片清算和优化.
- 利用X射线晶体学来阐明SN3-1.0的抑制机制.
- 在临床前模型中进行了全面的安全性和药理动力学评估.
主要成果:
- SN3-1显示出强大的NLRP3抑制,具有良好的安全性和药理动力学特征.
- X射线结晶学揭示了SN3-1抑制作用的分子基础.
- 在涉及NLRP3激活的疾病模型中,SN3-1表现出显著的治疗疗效.
结论:
- SN3-1是治疗开发的有希望的NLRP3抑制剂候选者.
- 基于深度学习的策略加快了发现和优化强效抑制剂的速度.
- 这项工作扩大了用于发现新型NLRP3抑制剂的工具包.
相关概念视频
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...